ZyVersa TherapeuticsZVSA
Market Cap: 3.21M
About: ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Employees: 7
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 0
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more funds holding
Funds holding: 6 [Q4 2023] → 8 (+2) [Q1 2024]
10.79% less ownership
Funds ownership: 12.29% [Q4 2023] → 1.5% (-10.79%) [Q1 2024]
53% less capital invested
Capital invested by funds: $181K [Q4 2023] → $84.9K (-$96.6K) [Q1 2024]
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
HC Wainwright & Co. Ed Arce | 6,134%upside $240 | Buy Reiterated | 26 Mar 2024 |
HC Wainwright & Co. Ed Arce | 6,134%upside $240 | Buy Maintained | 12 Mar 2024 |
HC Wainwright & Co. Ed Arce | 12,368%upside $480 | Buy Reiterated | 29 Feb 2024 |
Financial journalist opinion
Based on 3 articles about ZVSA published over the past 30 days